According to Reuters today, starting from Tuesday local time,Wall StreetBegin to look favorablySoftBankCompany SupportedGenetic Testing Companies Tempus AI, the company has AI-driven clinical and molecular databases, which is thought to lead to more powerful diagnostic and testing tools.
Tempus AI is headquartered in Chicago, USA, and sells its products to clinicians and hospital systems.Genomic diagnostic testing products, coveringOncology,Psychiatry, Radiology and Cardiologyand other fields.
includeJPMorgan ChaseSeven brokerages, including Morgan Stanley, Bank of America Global Research and Stifel, gave the company its first“Buy” or “Overweight” rating, TD Cowen gave the highest target price of $50.
JPMorgan Chase predicts that Tempus' revenue will grow by about 33% by 2027. The company expects to achieve core profitability in the second half of 2025. It said Tempus has successfully achievedUnique clinical genomic data monetization, which differentiates Tempus from other competitors.
Morgan Stanley predicts that the company's revenue will grow by 27% by 2028 and is expected to achieveCore profit break-even.
Bank of America Global Research said Tempus also has room to further expand existing relationships with biotech and big pharma companies and add new clients.
Tempus AI’s net loss widened to $289.8 million in fiscal 2023 from $214.1 million the year before, while total revenue grew 65.81% to $531.8 million, according to the report. But according to regulatory filings, revenue from its AI applications business accounted for about 11% of total revenue. Tempus describes its AI applications revenue as “Not relevant”.